Invitrall
Curitiba
About Invitrall
Over 90% of drugs fail in clinical trials, largely due to the limited representativeness of pre-clinical models. Traditional models’whether animal or in vitro’fail to effectively capture humans' complexity and genetic diversity. At Invitrall, we are overcoming this challenge. We develop advanced diseases in vitro models that represent human genetic diversity, providing innovative solutions to test the safety and efficacy of pharmaceutical and cosmetic products. Our technology bridges the gap left by traditional experimental models, helping to accelerate the development of therapies for various diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $250.0K
- Funding stage: Seed
- Last round: Pre-Seed (Jul 2024)
- Website: invitrall.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/invitrall-195375 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.